Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Frequently asked questions
What sector does Advicenne (ALDVI) operate in?
Advicenne belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Advicenne (ALDVI) current stock price?
As of the latest data, Advicenne stock price is €1.69, with a previous close of €1.69.
What is Advicenne (ALDVI) current market capitalization?
Advicenne market cap is approximately 24.86 million.
What is Advicenne (ALDVI) Earnings Per Share (EPS)?
The trailing EPS is -€0.65, and the forward EPS is -€0.44.
Does Advicenne (ALDVI) pay dividends?
No. Advicenne does not pay a dividend.
What is Advicenne (ALDVI) beta (volatility) score?
Advicenne has a beta of 0.930, meaning its volatility is roughly in line with the market.
